Merck opened its defence on Thursday in the second product liability trial over its arthritis medicine, countering claims that it did not study whether Vioxx might cause more heart ailments than other pain relievers. Merck researcher Dr Briggs Morrison told jurors the company conducted several studies of Vioxx before putting it on the market in May 1999, each concluding that Vioxx posed no threats to heart health.